Sarki A Abdulkadir

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/8599901/publications.pdf

Version: 2024-02-01

50 papers	2,900 citations	257450 24 h-index	254184 43 g-index
52 all docs	52 docs citations	52 times ranked	4930 citing authors

#	Article	IF	Citations
1	A phase II study of sEphB4-HSA in metastatic castration-resistant prostate cancer.. Journal of Clinical Oncology, 2022, 40, 84-84.	1.6	0
2	A Genome-Wide CRISPR Activation Screen Identifies PRRX2 as a Regulator of Enzalutamide Resistance in Prostate Cancer. Cancer Research, 2022, 82, 2110-2123.	0.9	11
3	A MYC inhibitor selectively alters the MYC and MAX cistromes and modulates the epigenomic landscape to regulate target gene expression. Science Advances, 2022, 8, eabh3635.	10.3	21
4	Development of heterobifunctional proteomimetic polymers for delivery of MYC inhibitory peptides and targeted MYC degradation.. Journal of Clinical Oncology, 2022, 40, e15049-e15049.	1.6	0
5	Turning Up the Heat on MYC: Progress in Small-Molecule Inhibitors. Cancer Research, 2021, 81, 248-253.	0.9	24
6	Macrophages expedite cell proliferation of prostate intraepithelial neoplasia through their downstream target ERK. FEBS Journal, 2021, 288, 1871-1886.	4.7	12
7	Early-onset metastatic and clinically advanced prostate cancer is a distinct clinical and molecular entity characterized by increased TMPRSS2â€“ERG fusions. Prostate Cancer and Prostatic Diseases, 2021, 24, 558-566.	3.9	9
8	Activated ALK Cooperates with N-Myc via Wnt/Î²-Catenin Signaling to Induce Neuroendocrine Prostate Cancer. Cancer Research, 2021, 81, 2157-2170.	0.9	24
9	Posttranslational regulation of FOXA1 by Polycomb and BUB3/USP7 deubiquitin complex in prostate cancer. Science Advances, 2021, 7, .	10.3	37
10	Inflammatory bowel disease induces inflammatory and pre-neoplastic changes in the prostate. Prostate Cancer and Prostatic Diseases, 2021, , .	3.9	7
11	FIREWORKS: a bottom-up approach to integrative coessentiality network analysis. Life Science Alliance, 2021, 4, e202000882.	2.8	29
12	Advanced glycation endâ€products (AGEs) are lower in prostate tumor tissue and inversely related to proportion of West African ancestry. Prostate, 2021, , .	2.3	1
13	Genomic Profiling of Prostate Cancers from Men with African and European Ancestry. Clinical Cancer Research, 2020, 26, 4651-4660.	7.0	68
14	Histone methyltransferase DOT1L coordinates AR and MYC stability in prostate cancer. Nature Communications, 2020, 11, 4153.	12.8	62
15	Association between inflammatory bowel disease and prostate cancer: A largeâ€scale, prospective, populationâ€based study. International Journal of Cancer, 2020, 147, 2735-2742.	5.1	28
16	Evaluating the clinical, environmental, genetic, and genomic profile of men with early-onset aggressive prostate cancer (PCa).. Journal of Clinical Oncology, 2020, 38, e17517-e17517.	1.6	0
17	Inhibition of PIM kinase with fractionated radiation and docetaxel in preclinical prostate cancer models.. Journal of Clinical Oncology, 2020, 38, e17534-e17534.	1.6	0
18	A phase II study of sEphB4-HSA in metastatic castration-resistant prostate cancer (mCRPC).. Journal of Clinical Oncology, 2020, 38, TPS274-TPS274.	1.6	0

#	Article	IF	Citations
19	EPHB4 inhibition activates ER stress to promote immunogenic cell death of prostate cancer cells. Cell Death and Disease, 2019, 10, 801.	6.3	38
20	Nivolumab in Metastatic Adrenocortical Carcinoma: Results of a Phase 2 Trial. Journal of Clinical Endocrinology and Metabolism, 2019, 104, 6193-6200.	3.6	79
21	Small-Molecule MYC Inhibitors Suppress Tumor Growth and Enhance Immunotherapy. Cancer Cell, 2019, 36, 483-497.e15.	16.8	247
22	Organoids Increase the Predictive Value of in vitro Cancer Chemoprevention Studies for in vivo Outcome. Frontiers in Oncology, 2019, 9, 77.	2.8	4
23	Prostate Stroma Increases the Viability and Maintains the Branching Phenotype of Human Prostate Organoids. IScience, 2019, 12, 304-317.	4.1	59
24	Palladium-Catalyzed Coupling Reactions on Functionalized 2-Trifluoromethyl-4-chromenone Scaffolds: Synthesis of Highly Functionalized Trifluoromethyl Heterocycles. Synthesis, 2019, 51, 1342-1352.	2.3	11
25	The Role of Castration-Resistant Bmi1+Sox2+ Cells in Driving Recurrence in Prostate Cancer. Journal of the National Cancer Institute, 2019, 111, 311-321.	6.3	27
26	Age-related variation in gene alteration frequency in metastatic prostate cancer.. Journal of Clinical Oncology, 2019, 37, 178-178.	1.6	0
27	Evaluating the clinical, environmental, genetic, and genomic profile of men with early-onset aggressive prostate cancer (PCa).. Journal of Clinical Oncology, 2019, 37, TPS333-TPS333.	1.6	0
28	Multi-faceted immunomodulatory and tissue-tropic clinical bacterial isolate potentiates prostate cancer immunotherapy. Nature Communications, 2018, 9, 1591.	12.8	64
29	A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer. Journal of Visualized Experiments, 2018, , .	0.3	6
30	Anaplastic Lymphoma Kinase Mutation (ALK F1174C) in Small Cell Carcinoma of the Prostate and Molecular Response to Alectinib. Clinical Cancer Research, 2018, 24, 2732-2739.	7.0	30
31	Targeting FOXA1-mediated repression of TGF-Î² signaling suppresses castration-resistant prostate cancer progression. Journal of Clinical Investigation, 2018, 129, 569-582.	8.2	116
32	Overcoming immunosuppression in bone metastases. Critical Reviews in Oncology/Hematology, 2017, 117, 114-127.	4.4	31
33	Organoids model distinct Vitamin E effects at different stages of prostate cancer evolution. Scientific Reports, 2017, 7, 16285.	3.3	19
34	Modeling African American prostate adenocarcinoma by inducing defined genetic alterations in organoids. Oncotarget, 2017, 8, 51264-51276.	1.8	14
35	Bmi1 marks distinct castration-resistant luminal progenitor cells competent for prostate regeneration and tumour initiation. Nature Communications, 2016, 7, 12943.	12.8	52
36	KAT8 Regulates Androgen Signaling in Prostate Cancer Cells. Molecular Endocrinology, 2016, 30, 925-936.	3.7	24

#	Article	IF	Citations
37	Emerging therapeutic targets in bladder cancer. Cancer Treatment Reviews, 2015, 41, 170-178.	7.7	108
38	PIM Kinase Inhibitor AZD1208 for Treatment of MYC-Driven Prostate Cancer. Journal of the National Cancer Institute, 2015, 107, .	6.3	62
39	RNAi Screen Identifies a Synthetic Lethal Interaction between PIM1 Overexpression and PLK1 Inhibition. Clinical Cancer Research, 2014, 20, 3211-3221.	7.0	18
40	A Functional Variant in NKX3.1 Associated with Prostate Cancer Risk in the Selenium and Vitamin E Cancer Prevention Trial (SELECT). Cancer Prevention Research, 2014, 7, 950-957.	1.5	22
41	Decreased mitochondrial SIRT3 expression is a potential molecular biomarker associated with poor outcome in breast cancer. Human Pathology, 2014, 45, 1071-1077.	2.0	68
42	Antioxidant Treatment Promotes Prostate Epithelial Proliferation in Nkx3.1 Mutant Mice. PLoS ONE, 2012, 7, e46792.	2.5	17
43	Nkx3.1 and Myc crossregulate shared target genes in mouse and human prostate tumorigenesis. Journal of Clinical Investigation, 2012, 122, 1907-1919.	8.2	53
44	SIRT3 Is a Mitochondria-Localized Tumor Suppressor Required for Maintenance of Mitochondrial Integrity and Metabolism during Stress. Cancer Cell, 2010, 17, 41-52.	16.8	705
45	Pim1 kinase synergizes with c-MYC to induce advanced prostate carcinoma. Oncogene, 2010, 29, 2477-2487.	5.9	120
46	Haploinsufficient Prostate Tumor Suppression by Nkx3.1. Journal of Biological Chemistry, 2007, 282, 25790-25800.	3.4	27
47	Haploinsufficiency at the Nkx3.1 locus. Cancer Cell, 2003, 3, 273-283.	16.8	133
48	Overexpression of the oncogenic kinase Pim-1 leads to genomic instability. Cancer Research, 2003, 63, 8079-84.	0.9	68
49	Conditional Loss of Nkx3.1 in Adult Mice Induces Prostatic Intraepithelial Neoplasia. Molecular and Cellular Biology, 2002, 22, 1495-1503.	2.3	220
50	Tissue factor expression and angiogenesisin human prostate carcinoma. Human Pathology, 2000, 31, 443-447.	2.0	124